Intensive Glycemic Control and Skeletal Health Study

PHASE3CompletedINTERVENTIONAL
Enrollment

7,287

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
AtherosclerosisCardiovascular DiseasesHypercholesterolemiaHypertensionDiabetes MellitusCoronary Disease
Interventions
DRUG

hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents

type 2 diabetes treatments, per standard of care

Trial Locations (5)

27106

Wake Forest University, Winston-Salem

38104

Veterans Affairs, Memphis

44106

Case Western Reserve University, Cleveland

55404

Berman Center for Outcomes & Clinical Research, Minneapolis

Unknown

Population Health Research Institute, Hamilton

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of California, San Francisco

OTHER

NCT00324350 - Intensive Glycemic Control and Skeletal Health Study | Biotech Hunter | Biotech Hunter